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The role of neo-angiogenesis in prostate cancer (PCA) growth and metastasis is well established, 
but the development of effective and non-toxic pharmacological inhibitors of angiogenesis 
remains an unaccomplished goal. In this regard, targeting aberrant angiogenesis through non-
toxic phytochemicals could be an attractive angiopreventive strategy against PCA. The rationale 
of the present study was to compare the anti-angiogenic potential of four pure diastereoisomeric 
flavonolignans, namely silybin A, silybin B, isosilybin A and isosilybin B, which we established 
previously as biologically active constituents in Milk Thistle extract. Results showed that oral 
feeding of these flavonolignans (50 and 100 mg/kg body weight) effectively inhibit the growth of 
advanced human PCA DU145 xenografts. Immunohistochemical analyses revealed that these 
flavonolignans inhibit tumor angiogenesis biomarkers (CD31 and nestin) and signaling 
molecules regulating angiogenesis (VEGF, VEGFR1, VEGFR2, phospho-Akt and HIF-1α) 
without adversely affecting the vessel-count in normal tissues (liver, lung, and kidney) of tumor 
bearing mice. These flavonolignans also inhibited the microvessel sprouting from mouse dorsal 
aortas ex vivo, and the VEGF-induced cell proliferation, capillary-like tube formation and 
invasiveness of human umbilical vein endothelial cells (HUVEC) in vitro. Further studies in 
HUVEC showed that these diastereoisomers target cell cycle, apoptosis and VEGF-induced 
signaling cascade. Three dimensional growth assay as well as co-culture invasion and in 
vitro angiogenesis studies (with HUVEC and DU145 cells) suggested the differential 
effectiveness of the diastereoisomers toward PCA and endothelial cells. Overall, these studies 
elucidated the comparative anti-angiogenic efficacy of pure flavonolignans from Milk Thistle 
and suggest their usefulness in PCA angioprevention. 
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Abstract
The role of neo-angiogenesis in prostate cancer (PCA) growth and metastasis is well established, but the development of
effective and non-toxic pharmacological inhibitors of angiogenesis remains an unaccomplished goal. In this regard,
targeting aberrant angiogenesis through non-toxic phytochemicals could be an attractive angiopreventive strategy against
PCA. The rationale of the present study was to compare the anti-angiogenic potential of four pure diastereoisomeric
flavonolignans, namely silybin A, silybin B, isosilybin A and isosilybin B, which we established previously as biologically
active constituents in Milk Thistle extract. Results showed that oral feeding of these flavonolignans (50 and 100 mg/kg body
weight) effectively inhibit the growth of advanced human PCA DU145 xenografts. Immunohistochemical analyses revealed
that these flavonolignans inhibit tumor angiogenesis biomarkers (CD31 and nestin) and signaling molecules regulating
angiogenesis (VEGF, VEGFR1, VEGFR2, phospho-Akt and HIF-1a) without adversely affecting the vessel-count in normal
tissues (liver, lung, and kidney) of tumor bearing mice. These flavonolignans also inhibited the microvessel sprouting from
mouse dorsal aortas ex vivo, and the VEGF-induced cell proliferation, capillary-like tube formation and invasiveness of
human umbilical vein endothelial cells (HUVEC) in vitro. Further studies in HUVEC showed that these diastereoisomers target
cell cycle, apoptosis and VEGF-induced signaling cascade. Three dimensional growth assay as well as co-culture invasion
and in vitro angiogenesis studies (with HUVEC and DU145 cells) suggested the differential effectiveness of the
diastereoisomers toward PCA and endothelial cells. Overall, these studies elucidated the comparative anti-angiogenic
efficacy of pure flavonolignans from Milk Thistle and suggest their usefulness in PCA angioprevention.
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Introduction
Prostate cancer (PCA) is the most frequently diagnosed non-
cutaneous malignancy among men in the United States, and is the
second leading cause of cancer-related deaths [1]. Clinical and
experimental evidence have suggested that human tumors could
persist for years as microscopic lesions in a state of dormancy and
their further growth is critically dependent upon attaining an
‘angiogenic phenotype’ [2,3,4,5]. ‘Angiogenic switches’ involving
the high VEGF and VEGF receptor (VEGFR) levels have been
identified and considered responsible for PCA progression from
low grade PIN (prostatic intraepithelial neoplasia) stage to high
grade PIN and further to more aggressive, poorly differentiated,
and androgen-independent malignant stages [6]. Furthermore,
angiogenesis level in PCA has been correlated directly with
Gleason score, tumor stage, progression, metastasis and survival
[6,7,8]. Therefore, targeting angiogenesis has been the subject of
several clinical investigations to improve the quality of life of
cancer patients [9,10,11]. Furthermore, preventing the onset of
angiogenesis in indolent tumors (referred as ‘angioprevention’) has
been suggested as a novel and rationale approach to control PCA
growth, malignant progression and metastasis to secondary sites.
About four decades ago, Judah Folkman first predicted the
potential role for anti-angiogenic inhibitors against solid cancers,
and to date, several angiogenesis inhibitors have been tested
against many malignancies [12,13,14,15]. Many of these inhibitors
have already been FDA approved for their use either alone or in
combination with cancer chemotherapeutic drugs [13,15,16]. For
example, humanized VEGF antibody was approved against
colorectal, brain, lung, and renal cancers [16]. Similarly, the
tyrosine kinase inhibitors sorafenib and sunitinib, which target
VEGFR activity, have been approved for use against advanced
renal cell carcinoma [16]. Although inhibiting angiogenesis in
cancer, in principle, is a sound preventive/therapeutic strategy,
the current approach of targeting a single molecule such as VEGF
or VEGFR is flawed, as cancer cells develop resistance through
circumventing these molecules and continue to spread vascular
networks [17]. Beside their limited efficacy in terms of improve-
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ment in patient’s survival, these treatment options are extremely
expensive and have shown unacceptable levels of toxicity [18,19].
Therefore, we rationalized the need to identify non-toxic natural
agents with broad spectrum anti-angiogenic efficacy; and in this
regard, in the present study, we focused on the anti-angiogenic
efficacy of four pure diastereoisomers from Milk Thistle (Silybum
marianum) extract, namely silybin A, silybin B, isosilybin A and
isosilybin B. These diastereoisomers are flavonolignans with an
identical flavonoid moiety and differ only in their configurations
about the lignan moiety, and their chemical and biological
properties have been detailed earlier [20,21,22,23,24]. Here, for
the first time we analyzed the angiopreventive efficacy of these
flavonolignans in PCA xenograft model and various ex vivo, in vivo
and in vitro angiogenesis assays.
Methods
Cell Line and Reagents
Human PCA DU145 cells were from ATCC (Manassas, VA)
and cultured as described earlier [25]. HUVEC were from Lonza
(Walkersville, MD) and were grown in EBM2 media with EGM-2
SingleQots supplements. Matrigel and invasion chamber were
from BD Biosciences (New Bedford, MA). TUNEL assay kit was
from Promega (Madison, WI). Carboxymethylcellulose (CMC),
Harris hematoxylin and b-actin antibody were from Sigma (St.
Louis, MO). DAB kit was from Vector Laboratories (Burlingame,
CA). Streptavidin and PCNA antibody were from Dako
(Carpinteria, CA). Antibodies for CD31, VEGF and nestin were
from Abcam (Cambridge, MA). Antibodies for VEGFR1,
VEGFR2, and HIF-1a [used for immunohistochemistry (IHC)
analysis] as well as antibodies for Cdk2, Cdk4, Cdc2, cyclin D1,
cyclin D3, cyclin B1, p21, p27, Skp 2, Cdc25A and Cdc25C and
normal goat serum were from Santa Cruz Biotechnology (Santa
Cruz, CA). p27 antibody was from Neomarkers (Fremont, CA)
and p21 antibody was from Upstate (Charlottesville, VA).
Antibodies recognizing the phosphorylated and/or total protein
levels of VEGFR1, VEGFR2, Src, ERK1/2, Akt, Bad, mTOR,
p70S6K, cleaved caspase 3, cleaved caspase 9, and goat anti-
rabbit HRP-conjugated secondary antibodies were from Cell
Signaling (Beverly, MA). ECL detection system and anti-mouse
Figure 1. Flavonolignans inhibit PCA DU145 xenograft growth through targeting proliferation and apoptosis. DU145 xenografts were
initiated and mice were administered either vehicle (CMC) or 50 and 100 mg/kg body weight doses of each diastereoisomer. (A) Tumor volume was
measured and plotted as a function of time (days). Each value in the curves is mean 6 SEM of 10–12 mice. (B–D) Xenograft tissues were analyzed for
PCNA, TUNEL and cleaved caspase-3 (CC3) by IHC. The data shown in the bar diagrams is the mean6 SEM of 4–5 samples. Abbreviations: Sil A: Silybin
A; Sil B: Silybin B; Iso A: Isosilybin A, Iso B: Isosilybin B; *, p # 0.001; #, p # 0.01; $, p # 0.05.
doi:10.1371/journal.pone.0034630.g001
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HRP-conjugated secondary antibody were from GE Healthcare
(Buckinghamshire, UK). VEGF was from R & D (Minneapolis,
MN). Silybin A, silybin B, isosilybin A and isosilybin B were
isolated (purity .97%) from powdered extract of the fruits of
Silybum marianum (L.) Gaertn. [obtained from Euromed, S.A.
(Barcelona, Spain)]. The hybrid chromatographic/precipitative
techniques and procedures for the gram scale purification of these
flavonolignans are already reported previously [26].
In Vivo Tumor Xenograft Study
Athymic (nu/nu) male nude mice were from the NCI (Frederick,
MD). The treatment protocol was approved by the Institutional
Animal Care and Use Committee of the University of Colorado
Denver. About 3 6 106 DU145 cells were suspended in 50 mL of
serum free medium, mixed with 50 mL of matrigel, and injected
s.c. in the right flank of each mouse. The day following xenograft
implantation, mice were randomly divided into nine groups, and
all treatments were done by oral gavage as: Group I mice (vehicle
control group) with 200 mL of 0.5% CMC (w/v) in sterile water;
Groups II and III mice with 50 and 100 mg/kg body weight dose
of silybin A; Groups IV and V mice with 50 and 100 mg/kg body
weight dose of silybin B; Groups VI and VII mice with 50 and
100 mg/kg body weight dose of isosilybin A; and Groups VIII and
IX mice with 50 and 100 mg/kg body weight dose of isosilybin B,
respectively. All these treatments (5 days/week) were given in
200 mL of 0.5% CMC. As all four compounds have same
molecular weight (482.1), each dose-level was equimolar across
these agents. Once tumor xenograft growth commenced, tumor
sizes were measured twice weekly using digital caliper and tumor
volume was calculated by the formula: 0.5236 L1(L2)
2, where L1 is
long diameter, and L2 is short diameter.
IHC Analyses
Tumor samples were processed and immuno-stained following
published methods [27,28,29]. Percentage of PCNA, TUNEL,
cleaved caspase 3 and HIF-1a positive cells was calculated by
counting the number of positive stained cells (brown stained) and
the total number of cells at five arbitrarily selected fields from each
tumor at 400x magnification. Microvessels stained with CD31 and
nestin were quantified in 5 random microscopic (400x magnifica-
tion) fields per tumor. VEGF, VEGFR1, VEGFR2, pAktser473,
and Akt immunoreactivity was analyzed in 5 random areas for
each tumor tissue and was scored as 0+ (no staining), 1+ (weak
staining), 2+ (moderate staining), 3+ (strong staining), 4+ (very
strong staining).
Figure 2. Flavonolignans inhibit angiogenesis in vivo. DU145 xenograft tissues were analyzed for CD31, nestin, VEGF and VEGFR2 by IHC.
Quantitative analyses were performed using Zeiss Axioscope 2 microscope (Carl Zeiss, Germany) and photographs were originally captured (at 400x)
with a Carl Zeiss AxioCam MrC5 camera with Axiovision Rel 4.5 software. The data shown in the bar diagrams is the mean 6 SEM of 4–5 samples.
Abbreviations: Sil A: Silybin A; Sil B: Silybin B; Iso A: Isosilybin A, Iso B: Isosilybin B; *, p # 0.001.
doi:10.1371/journal.pone.0034630.g002
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Ex Vivo Capillary Formation Assay
Aortas isolated from mice were cleaned, cut into small
fragments and placed on matrigel-covered wells and covered with
another 100 mL matrigel. After these aortas were cultured for
24 h, the medium (complete HUVEC media) was replaced with or
without flavonolignans (30 and 60 mM). Treatments were replaced
after 48 h. After 6 days of total incubation, vessels sprouting from
the aortas were photographed using Cannon Power Shot A640
camera on Zeiss inverted microscope.
Tube Formation Assay
HUVEC (46104) were cultured in 1 mL EBM2 (supplemented
with 0.5% FBS and 4 ng/mL VEGF) with various diastereoiso-
mers (5–30 mM) on matrigel coated plates. After 9 h of incubation,
tubular structure formation was quantified by calculating the tube
length (at 100x) with Zeiss inverted microscope using Cannon
Power Shot A640 camera and AxioVision Rel.4.7 software. In a
related experiment, DU145 cells were treated with 30 mM dose of
each flavonolignan for 72 h, and fresh media (0.5% FBS) was
added and collected after 12 h (labeled as ‘conditioned media’).
The conditioned media mixed with 0.5% FBS supplemented
EBM2 media (75:25 ratio) was then added to HUVEC and tube
formation was studied as described above.
Cell Viability Assay
HUVEC were treated with or without VEGF (10 ng/mL) and
different concentrations of flavonolignans (5–30 mM). After the
desired treatment, total cell number was determined using a
hemocytometer.
Transwell Invasion Assay
In this assay, the bottom chambers of Transwell were filled with
EBM2 media containing 0.5% FBS supplemented with 4 ng/mL
VEGF, and in the top chambers HUVEC (46104) were seeded in
500 mL EBM2 (0.5% FBS) plus 30 mM dose of each flavonolignan.
After 10 h, invasive cells were quantified as described previously
[30,31]. Similar assay was also performed with DU145 cells plated
in the bottom chamber (RPMI media with 0.5% serum) and
HUVEC (EBM2 media with 0.5% serum) in the upper chamber.
In two separate experiments, flavonolignans were added either in
the upper chambers or in the lower chambers and invasiveness of
HUVEC was studied in each case.
Cell Cycle Distribution and Apoptosis
Cell cycle distribution (saponin/PI staining) and apoptosis
(Annexin-PI staining) were analyzed by FACS [32,33].
Figure 3. Flavonolignans decrease VEGFR1, HIF-1a, phosphorylated and total Akt levels in DU145 xenografts. DU145 xenograft tissues
were analyzed for VEGFR1, HIF-1a, phosphorylated Aktser473 and total Akt levels by IHC. Quantitative analyses were performed using Zeiss Axioscope
2 microscope (Carl Zeiss, Germany) and photographs were originally captured (at 400x) with a Carl Zeiss AxioCam MrC5 camera with Axiovision Rel
4.5 software. The data shown in the bar diagrams is the mean 6 SEM of 4–5 samples. Abbreviations: Sil A: Silybin A; Sil B: Silybin B; Iso A: Isosilybin A,
Iso B: Isosilybin B; *, p # 0.001.
doi:10.1371/journal.pone.0034630.g003
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Immunoblotting
HUVEC were treated with 30 mM dose of each flavonolignan
with or without VEGF stimulation, lysates were prepared and
analyzed by standard immunoblotting method as described earlier
[33,34]. a-tubulin and b-actin were used to confirm equal protein
loading.
Three Dimensional Spheroid Formation Assay
In 24 well plates, 100 mL of matrigel was added. Thereafter,
100 ml of RPMI-1640 and matrigel mixture (50:50) containing
,16103 DU145 cells was added. After 15 min, 1 mL RPMI-1640
medium with 10% FBS containing DMSO vehicle or 90 mM
concentration of each flavonolignan was added in the well;
treatments were replaced every 48 h for 2 weeks. At the end of the
experiment, spheroid formation was counted under Zeiss inverted
microscope at 100x.
Statistical Analyses
Statistical analyses were performed using Sigma Stat software
version 2.03 (Jandel Scientific, San Rafael, CA). The statistical
significance of differences between control and treated-groups was
determined by Student’s t test and p , 0.05 value was considered
significant. One way ANOVA followed by Tukey’s test was used
for multiple comparisons. The autoradiograms/bands were
scanned, and mean density of bands (where mentioned) was
determined using Adobe Photoshop 6.0 (Adobe Systems, San Jose,
CA).
Results
Effect of Flavonolignans on PCA DU145 Xenograft
Growth
In terms of anti-tumor efficacy, the oral administration of
flavonolignans effectively inhibited the growth of DU145 xeno-
grafts in nude mice, and this was discernible from the third week
onwards (Fig. 1A). At the end of the experiment (10 wks), silybin A
treatment inhibited the tumor volume by 44 and 50% with 50 and
100 mg/kg body weight doses, respectively (p, 0.05) (Fig. 1A);
while silybin B inhibited the tumor volume by 38 and 47% at same
doses, respectively (p, 0.05) (Fig. 1A). In isosilybin A treated mice,
tumor volume was inhibited by 44 and 50% (p, 0.05) (Fig. 1A),
while in mice treated with isosilybin B the tumor volume was
inhibited by 46 and 67% with 50 and 100 mg/kg body weight
doses, respectively (p, 0.05) (Fig. 1A). Overall, isosilybin B was
most effective in inhibiting the DU145 xenograft growth, followed
by silybin A or isosilybin A and silybin B. Although, these
differences in the biological effect of each diastereoisomer did not
achieve statistical significance; these results were consistent with
previously reported in vitro studies [21,22].
At the time of necropsy, all animals were examined for gross
pathology, and we did not observe any signs of abnormality in all
the vital organs examined. Furthermore, the administration of
these compounds through oral gavage did not cause any
significant change in the diet consumption pattern or body weight
gain of mice (data not shown). Also, we did not observe any
adverse effect in terms of general behavior of animals, suggesting
an overall safe nature of these compounds.
Figure 4. Feeding of pure flavonolignans did not affect
angiogenesis and normal histology in non-target organs. (A–
B) Lungs, liver and kidneys from each mouse were collected and
analyzed for CD31 immunoreactivity as well as for histopathological
analyses. Quantitative analyses were performed using Zeiss Axioscope 2
microscope (Carl Zeiss, Germany) and photographs were originally
captured (at 400x) with a Carl Zeiss AxioCam MrC5 camera with
Axiovision Rel 4.5 software. Abbreviations: Sil A: Silybin A; Sil B: Silybin B;
Iso A: Isosilybin A, Iso B: Isosilybin B.
doi:10.1371/journal.pone.0034630.g004
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Effect of Flavonolignans on Proliferation and Apoptosis
in DU145 Xenografts
The IHC analysis of DU145 tumor samples showed that
flavonolignans treatment significantly inhibits the immunostaining
for PCNA (a biomarker for cell proliferation) (Fig. 1B), but
increases the TUNEL and cleaved-caspase 3 positive cells
(biomarkers for apoptosis) (Fig. 1C and 1D). Though statistically
significant, the effect of flavonolignans on proliferation and
apoptosis related biomarker was modest, and could not completely
explain the observed slower xenograft growth and close to 50%
growth inhibition with the flavonolignan treatment (Fig. 1A).
Therefore, next we analyzed the tumor tissues for flavonolignans
effect on angiogenesis, which is absolutely necessary for the tumors
to grow beyond 1–2 mm size [3].
Effect of Flavonolignans on Angiogenesis in DU145
Xenografts
To investigate whether these individual flavonolignans inhibited
the xenograft growth by suppressing tumor angiogenesis, we
stained the tumor section with CD31 (a biomarker for matured
microvessels) and nestin (a biomarker for immature and newly
formed microvessels). All four compounds inhibited the microves-
sel density, both mature and newly forming, but isosilybin B was
relatively more effective in its inhibitory effect on nestin-positive
Figure 5. Flavonolignans inhibit angiogenesis in ex vivo and in vitro models. (A) Flavonolignans inhibit angiogenesis ex vivo. Mouse
aortas were plated on matrigel and treated with flavonolignans. The arrows in the picture mark the emerging vessels from the aortas. (B)
Flavonolignans inhibit VEGF-induced tube formation in HUVEC. HUVEC were plated on matrigel and effect of diastereoisomers treatment
on VEGF-induced tube formation was analyzed. Representative tubular network photomicrographs are shown at 100x (top panel). Tube length was
quantified as detailed in ‘Methods’ (bottom panel). Abbreviations: Sil A: Silybin A; Sil B: Silybin B; Iso A: Isosilybin A, Iso B: Isosilybin B; *, p # 0.001.
doi:10.1371/journal.pone.0034630.g005
Figure 6. Flavonolignans inhibit VEGF-induced proliferation and invasion in HUVEC. (A) HUVEC were induced with VEGF and treated with
each flavonolignan in 0.5% serum media, and total cell number was analyzed after 24 h. (B) HUVEC were plated in the upper chamber with DMSO or
individual diastereoisomer, while VEGF was added in the lower chamber and HUVEC invasion was studied. Abbreviations: Sil A: Silybin A; Sil B: Silybin
B; Iso A: Isosilybin A, Iso B: Isosilybin B; *, p # 0.001; #, p # 0.01; $, p # 0.05.
doi:10.1371/journal.pone.0034630.g006
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microvessels (Fig. 2). VEGF is a potent pro-angiogenic factor
[17,35], and IHC analyses of tumor sections clearly showed that
treatment with these diastereoisomers decreases both VEGF and
VEGFR2 expression in tumor tissues (Fig. 2). Notably, except
silybin A, VEGFR1 expression was also significantly decreased by
these agents (Fig. 3). Overall, isosilybin B was relatively more
potent in its efficacy on VEGF, VEGFR2 and VEGFR1
expression. HIF-1a is the master transcriptional factor that is
stabilized under hypoxic conditions in growing tumors and
controls tumor metabolism as well as expression of pro-angiogenic
factors such as VEGF [36,37,38]. Although HIF-1a stabilization
occurs under low oxygen conditions, its expression is also
controlled by the serine/threonine kinase Akt [39]. Akt also plays
an important role in multiple cellular processes, such as cell
survival, apoptosis, migration and metabolism [40,41]. IHC
analyses of tumors showed that all four of the flavonolignans
strongly decrease HIF-1a and pAktser473 levels, with marginal
effect on total Akt expression only by isosilybin A and isosilybin B
(Fig. 3).
Effect of Flavonolignans on Angiogenesis in Non-target
Organs
To confirm that the anti-angiogenic effects of these flavono-
lignans are specific to tumor tissues, we analyzed the non-target
organs (liver, lung, and kidney) for CD31 expression to determine
the microvessels density. There was no difference in the
microvessel density in liver, lung and kidney between control
and mice fed with pure flavonolignans (Fig. 4A, CD31
quantification data not shown). H & E analyses also showed that
these diastereoisomers have no adverse effect on the histology of
normal organs (Fig. 4B).
Effect of Flavonolignans on Angiogenesis in Ex Vivo and
In Vitro Assays
We further examined the anti-angiogenic activity of the
flavonolignans in ex vivo capillary formation assay using mouse
dorsal aortas. After six days of culture on matrigel under
angiogenic conditions, we observed a significant number of vessels
sprouting from the mouse aortas (marked by arrows), which was
inhibited in a dose-dependent manner by flavonolignans treatment
(Fig. 5A).
One of the important steps during neo-angiogenesis is the
formation and merging of tubes produced by endothelial cells
forming a complex network of vessels and capillaries [42,43]. To
understand the effect of flavonolignans on this biological event, we
performed tube formation assay. As shown in Fig. 5B, bottom
panel, all four compounds significantly inhibited the VEGF-
induced tube length in HUVEC. As shown in the pictures (Fig. 5B,
top panel), VEGF treatment induced the formation of tubular
networks by HUVEC, which was disrupted by flavonolignan
treatments.
Effect of Flavonolignans on VEGF-induced Proliferation
and Chemotactic Motility
VEGF plays an important role during neo-angiogenesis through
its mitogenic and motogenic effect on endothelial cells [17,35]. In
our studies, VEGF treatment induced the HUVEC growth that
was strongly inhibited by flavonolignans treatment (Fig. 6A). Such
treatments also inhibited the chemotactic motility of HUVEC
towards VEGF in the Transwell invasion assay (Fig. 6B).
Importantly, isosilybin B was the least effective compared to the
other diastereoisomers in terms of inhibitory effect on the
chemotactic motility of HUVEC.
Effect of Flavonolignans on Viability, Cell Cycle
Progression and Apoptosis in HUVEC
To further elucidate the biological effect of these flavonolignans
on endothelial cells, we analyzed viability, cell cycle and apoptosis
in HUVEC. As shown in Fig. 7A, the four flavonolignans (5–
30 mM) inhibited HUVEC viability in a dose- and time-dependent
manner. Cell cycle analyses revealed that all the diastereoisomers
induced G1 arrest after 24 h of treatment, but only silybin A,
silybin B and isosilybin A also caused G2/M arrest (Fig. 7B). After
48 h of treatment, the noticeable effect of silybin A, silybin B and
isosilybin A in HUVEC was the induction of G2/M arrest, which
was missing with isosilybin B treatment (Fig. 7B). Isosilybin A
treatment (at 30 mM) significantly induced S-phase arrest after
48 h of treatment, which could be linked to strong apoptotic death
induced by isosilybin A (Fig. 7B).
We next examined the effect of these flavonolignans on various
cell cycle regulatory molecules, namely cyclins, Cdks and Cdk
inhibitors as well as their regulators Skp2 and phosphatases
Cdc25. As shown in Fig. 7C, the four flavonolignans decreased the
levels of Cdk2 and Cdk4 with marginal effect on Cdc2. These
compounds also decreased the levels of cyclin D1, cyclin D3,
cyclin A, and cyclin B1. Silybin A and isosilybin A moderately
increased the p27 expression, but it was decreased by isosilybin B
(Fig. 7C). On the contrary, p21 expression was decreased by
silybin A, silybin B and isosilybin A but not by isosilybin B
(Fig. 7C). However, all four diastereoisomers strongly decreased
the expression of Skp2 and Cdc25C with no or moderate
inhibitory effect on Cdc25A level (Fig. 7C). These results suggested
that these four diastereoisomers have few similar (but differing in
the extent) and few contrasting effects on the expression of cell
cycle regulatory molecules.
We then examined the effect of the pure flavonolignans (at
30 mM) on apoptosis after 36 h of treatment in HUVEC. As
shown in Fig. 7D, isosilybin B was the least efficacious in terms of
inducing apoptosis related morphological features (detachment
and rounding), signaling molecules involved in apoptosis (cPARP,
cleaved caspase 3 and 9) and percentage of apoptotic cell
population in HUVEC. Conversely, silybin A, silybin B and
isosilybin A strongly induced apoptotic death in HUVEC (Fig. 7D).
Effect of Flavonolignans on VEGF-induced Signaling in
HUVEC
Next, we examined flavonolignans effect on the VEGF-induced
signaling cascade that controls proliferation, motility and tube
formation in endothelial cells [35]. VEGF treatment strongly
increased the VEGFR2 phosphorylation at Ser1175 site, a reliable
marker for its activity, which was inhibited by pre-treatment with
flavonolignans (Fig. 8). Similarly, VEGF increased the phosphor-
Figure 7. Effect of flavonolignans on viability, cell cycle distribution and apoptosis in HUVEC. (A–B) HUVEC were treated with DMSO or
individual flavonolignan and analyzed for total cell number and cell cycle distribution. (C) HUVEC were treated with flavonolignans, and 24 h later,
total cell lysates were prepared and analyzed for cell cycle regulators. The densitometry values presented below the bands are ‘fold change’
compared to control after loading control (a-tubulin) normalization. (D) HUVEC were treated with flavonolignans (at 30 mM dose) for 36 h and
analyzed for morphology (representative photomicrographs are shown at 100x), levels of cPARP, cleaved caspase 3 and 9, and percentage apoptotic
cells. Abbreviations: Sil A: Silybin A; Sil B: Silybin B; Iso A: Isosilybin A, Iso B: Isosilybin B; *, p # 0.001; #, p # 0.01; $, p # 0.05.
doi:10.1371/journal.pone.0034630.g007
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ylation of VEGFR1, Src, ERK1/2, Akt, BAD, mTOR, and
p70S6K. As shown in Fig. 8, except ERK1/2 and mTOR,
phosphorylation at other sites was inhibited by these compounds
albeit to different extent. Compared to its other diastereoisomers,
isosilybin B was the least effective in terms of effect on the VEGF-
induced signaling molecules in HUVEC.
Differential Sensitivity of Flavonolignans Towards PCA
and Endothelial Cells
Earlier findings [20,21,22,24] and the present study suggested
that among the four pure flavonolignans, isosilybin B is the most
effective in terms of efficacy against PCA cells but, surprisingly, it
has the least efficacy in terms of its effect on HUVEC (inhibition of
chemotactic motility or apoptosis induction) (Figs. 6 and 7).
Therefore, we performed a series of experiments to elucidate the
relative efficacy of these four diastereoisomers against PCA cells
vis-à-vis endothelial cells. First, we analyzed their effect on the
three dimensional growth of DU145 cells in matrigel. Treatment
with these compounds strongly inhibited the number and size of
spheroid formed by DU145 cells with isosilybin B being most
effective (Fig. 9A). Next, we performed co-culture studies using
Transwell chambers. We plated HUVEC in the upper chamber,
while DU145 cells were cultured in the lower chamber. In two
separate experiments, HUVEC or DU145 cells were treated with
pure flavonolignans, and thereafter, HUVEC invasion through
matrigel was studied in each case. As shown in Fig. 9B, isosilybin B
was the most effective in decreasing the HUVEC migration when
DU145 cells were treated but was least effective when HUVEC
were treated.
To follow this, we treated DU145 cells with these diastereoiso-
mers (30 mM) and collected the conditioned media. The pro-
angiogenic potential of the conditioned media was analyzed in a
tube formation assay using HUVEC. As shown in Fig. 9C,
conditioned media from DU145 cells increased the tube length as
well as tubular network formed by HUVEC. Conditioned media
from the flavonolignan treated DU145 cells significantly decreased
the tube length as well as tubular network (Fig. 9C). In this assay
too, isosilybin B was the most effective diastereoisomer (Fig. 9C).
On the contrary, silybin A was more effective when HUVEC were
treated directly with these diastereoisomers (Fig. 5B). Together
these studies further confirmed the differential sensitivity of these
diastereoisomers towards PCA and endothelial cells.
Discussion
Neo-angiogenesis is the critical step in the development and
progression of most of the human cancers. Beyond the critical size
of 1–2 mm, oxygen and nutrients have difficulty in diffusing to the
core cells of the tumor, causing a state of cellular hypoxia. Under
hypoxic conditions, cancer cells secrete several pro-angiogenic
factors such as VEGF and bFGF, which cause recruitment of
endothelial cells from the neighboring blood vessels [6,44]. But the
continuous and excessive presence of pro-angiogenic stimuli in the
tumor microenvironment interferes with the normal maturation of
vessel network, and as a result, vessels in the tumor area show
abnormal morphology and physiology. Hence, it is possible to
specifically target abnormal tumor angiogenesis by inhibiting
endothelial cell recruitment as well as their proliferation in the
tumor microenvironment. Notably, the results from the present
study clearly suggest the strong efficacy of four pure flavonolignans
from Milk Thistle extract, on these aspects, which signifies their
angiopreventive efficacy against PCA. These findings are aslo
transnationally noteworthy, as currently, anti-angiogenic strategies
are extensively pursued towards preventing the progression of
Figure 8. Effect of flavonolignans on VEGF-induced signaling
cascade in HUVEC. HUVEC were serum starved for 22 h, treated with
diastereoisomers for 2 h and stimulated with VEGF (10 ng/ml) for
10 minutes. Total cell lysates were prepared and analyzed for
mentioned signaling molecules. The densitometry values presented
below the bands are ‘fold change’ compared to control after loading
control (b-actin) normalization.
doi:10.1371/journal.pone.0034630.g008
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diagnosed pre-malignant tumors or for the therapeutic regression
of the already advanced disease [16,45].
Milk thistle has been used for centuries to treat chronic liver
disease, and to protect the liver against toxins [46]. In recent years,
Milk thistle research use has grown significantly with close to two
dozen clinical trials underway or already completed evaluating its
efficacy against variety of diseases including chronic hepatitis,
diabetes, asthma, mushroom poisoning and various cancers (these
studies are listed at ClinicalTrials.gov). In the past, there have been
numerous efforts in isolating and purifying the individual
constituents in Milk thistle to better exploit its clinical usefulness.
Members of our team were the first to purify and elucidate seven
distinct flavonolignans from Milk Thistle extract, namely: silybin
A, silybin B, isosilybin A, isosilybin B, silydianin, silychristin, and
isosilychristin, and one flavonoid, taxifolin [47]. Their biological
effects as pure compounds were assessed on several anti-
proliferative end points in human PCA cell lines, where isosilybin
B ranked as the most potent flavonolignan for nearly all the end
points, including the inhibition of cell growth, clonogenic
potential, PSA and androgen receptor levels, and topo IIa
promoter activity [20,21,22,24]. Despite these advances in the
Milk Thistle research, the in vivo biological efficacy and related
toxicity of these pure flavonolignans remained unknown because
of insufficient compound quantities. In particular, isosilybin B was
the most challenging of the major diastereoisomer to purify, due to
its limited abundance in the natural extract [21] and its relatively
Figure 9. Differential effect of flavonolignans on human PCA DU145 cells and endothelial HUVEC in cell culture assays. (A) Effect of
flavonolignans (at 90 mM dose) on the three dimensional growth of DU145 cells was studied as detailed in ‘Materials and Methods’. Representative
spheroids photomicrographs are shown at 100x and 400x. (B) In Transwell invasion assay, either DU145 cells (plated in the lower chamber) or HUVEC
(plated in the upper chamber) were treated with individual diastereoisomers (at 30 mM dose), and HUVEC invasiveness was measured. (C) DU145 cells
were treated with individual diastereoisomers (at 30 mM dose) and conditioned media was collected. HUVEC were plated on matrigel along with 0.5%
FBS or conditioned media from different treatment groups; and tube formation was analyzed. Representative photomicrographs of tubular network
are shown at 100x. Abbreviations: Sil A: Silybin A; Sil B: Silybin B; Iso A: Isosilybin A, Iso B: Isosilybin B; CM: Conditioned media; *, p # 0.001; #, p #
0.01.
doi:10.1371/journal.pone.0034630.g009
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long retention time in most reverse-phase HPLC systems. The pre-
clinical or future clinical use of these pure compounds needed
advancement in their isolation; therefore, we developed a hybrid
chromatographic/precipitative technique for gram scale purifica-
tion of flavonolignan diastereoisomers from Milk Thistle extract
[26]. We believe that this is a major advancement towards the
future translational significance of these pure flavonolignans.
The results from the present study adequately proved that the
pure diastereoisomers from Milk Thistle have strong angiopre-
ventive efficacy through targeting the pro-angiogenic signaling in
PCA cells as well as in endothelial cells; the important component
of PCA microenvironment (Fig. 10). Furthermore, based upon the
overall in vitro and in vivo analyses, it is also clear that the
comparative efficacy of isosilybin B occupies two opposite ends in
terms of its effect on PCA cells and endothelial cells. Specifically, it
is the lead agent in terms of its efficacy against PCA cells but it is
the least effective agent against endothelial cells. On the contrary,
silybin A appears to be the most promising agent in terms of its
effects on endothelial cells. Therefore, it is prudent to suggest that
a defined mixture of silybin A and isosilybin B should be tested,
particularly in vivo, with an expectation of these two compounds
acting in concert to exert maximum benefits via targeting both the
tumor and the tumor microenvironment components.
In summary, the present study, for the first time, report the anti-
cancer efficacy of four flavonolignans from Milk Thistle extract in
an in vivo system of advanced stage human PCA. These results
further suggest the stereochemistry based differential efficacy of
these flavonolignans towards cancer and endothelial cells.
Furthermore, these results confirm the non-toxicity as well as
PCA specific anti-angiogenic effects of the pure diastereoisomers,
which suggest their usefulness in PCA angioprevention.
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